Purinergic Signalling, published by Springer, is a pivotal academic journal dedicated to the exploration of purinergic signaling pathways and their implications in various biological processes. Since its inception in 2004, the journal has made significant contributions to the fields of Cell Biology, Cellular and Molecular Neuroscience, and Molecular Biology, consistently ranking in the Q3 category in recent assessments. With a strong focus on the molecular mechanisms of purines and their roles in physiology and pathology, Purinergic Signalling serves as an essential resource for researchers and professionals seeking to understand the complexity of cellular communication. Although it does not offer open access, the journal ensures a broad dissemination of high-quality research findings, making it a vital tool for academic advancement in the fields of neuroscience and molecular biology. Its commitment to scholarly excellence is reflected in its Scopus rankings, where it is competitively positioned within its categories. As we approach its 20th anniversary in 2024, Purinergic Signalling continues to inspire and inform cutting-edge research in the dynamic landscape of life sciences.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

Genes & Diseases, published by KEAI PUBLISHING LTD, is a premier open-access journal dedicated to advancing the fields of genetics, biochemistry, and molecular biology. Established in 2014 and headquartered in Beijing, China, this journal has quickly risen to prominence, securing a place in the prestigious Q1 quartile in Biochemistry and Genetics (clinical), as well as Q2 in Cell Biology and Q1 in Molecular Biology as of 2023. With a commitment to disseminating cutting-edge research, Genes & Diseases serves as a critical platform for researchers, professionals, and students alike, ensuring that high-quality scientific work is openly accessible to the global community. The journal's exceptional impact is underscored by its selective Scopus rankings, which reflect its influence and relevance in key scientific domains, making it an essential resource for those exploring the intersections of genetics and disease pathology.

BRAIN PATHOLOGY, published by WILEY, is a leading journal in the fields of neurology, neuroscience, and pathology, recognized for its rigorous peer-review process and high-impact research contributions. With an impressive impact factor and consistently ranked in the Q1 quartile across multiple categories, BRAIN PATHOLOGY maintains a prominent status, with a Scopus ranking placing it among the top 10% of journals in its fields. Since its inception in 1990, the journal has served as a crucial platform for researchers and clinicians alike, disseminating groundbreaking findings that advance our understanding of brain diseases and injuries. Through its dedication to publishing high-quality, innovative research, BRAIN PATHOLOGY plays a vital role in shaping the future of brain pathology research. While it does not currently offer open access, articles can be accessed through institutional subscriptions. Researchers, professionals, and students are encouraged to contribute to and engage with this esteemed publication to foster knowledge and collaboration within this dynamic field.

Acta Neuropathologica Communications is a distinguished open-access journal published by BMC since 2013, focusing on the rapidly advancing fields of neurology, cellular and molecular neuroscience, and pathology. Located in the United Kingdom, this journal serves as a vital platform for researchers to disseminate significant findings that enhance our understanding of neurological disorders and their underlying mechanisms. With an impressive impact factor reflected in its Q1 ranking across multiple relevant categories, including Cellular and Molecular Neuroscience, Neurology (Clinical), and Pathology and Forensic Medicine, Acta Neuropathologica Communications stands out in the academic community for its rigorous peer-review process and commitment to high-quality research. The journal’s Scopus rankings highlight its global relevance, placing it in the top percentiles among leading research publications. Researchers, professionals, and students alike are encouraged to access and contribute to this essential resource, fostering a collaborative and informed approach to tackling the complexities of neuropathology and neuroscience.

CELLULAR AND MOLECULAR LIFE SCIENCES, published by SPRINGER BASEL AG, stands as a premier journal dedicated to advancing the field of cellular and molecular biology. With an impressive 2023 impact factor reflected in its Q1 rankings across key categories—including Cell Biology, Molecular Biology, and Pharmacology—it serves as a critical platform for researchers aiming to disseminate high-quality findings in these dynamic fields. Operated under an open access framework, the journal allows broader accessibility to groundbreaking research, fostering collaboration amongst scientists globally. Based in Switzerland, CELLULAR AND MOLECULAR LIFE SCIENCES has been at the forefront of scientific publishing since 1952, adapting to contemporary scientific challenges and trends, ultimately shaping the future of life sciences.

ANNALS OF NEUROLOGY, published by Wiley, stands as a leading journal in the field of neurology, renowned for its rigorous peer-reviewed articles that contribute significantly to the understanding of neurological disorders and advances in clinical practices. With an impressive impact factor and ranked Q1 in both neurology and clinical neurology categories, this journal positions itself among the top repositories of cutting-edge research, indexed in Scopus with exemplary ranks in the 98th and 97th percentiles respectively. Since its inception in 1977 and with a commitment to excellence extending to 2024 and beyond, ANNALS OF NEUROLOGY aims to disseminate groundbreaking studies and foster dialogue within the academic community, making it an essential resource for researchers, healthcare professionals, and students dedicated to neurology. Although it does not currently offer open access, its accessibility through institutional subscriptions facilitates widespread scholarly engagement.

Fetal and Pediatric Pathology, an esteemed journal published by TAYLOR & FRANCIS INC, is dedicated to advancing the field of pediatric and fetal medicine through the dissemination of high-quality research and clinical insights. With an ISSN of 1551-3815 and an E-ISSN of 1551-3823, the journal has been a key resource for researchers and practitioners since its inception in 1983. Based in the United Kingdom, it covers a broad spectrum of topics relevant to Medicine, Pathology and Forensic Medicine, and Pediatrics, Perinatology, and Child Health, consistently reflecting on contemporary challenges faced in these fields. The journal has attained a commendable Q3 ranking within its categories as of 2023, underlining its relevance in the academic community. Though not an open-access publication, the research presented in Fetal and Pediatric Pathology plays a pivotal role in informing practice, guiding future studies, and enhancing the understanding of diseases affecting fetuses and children. Its convergence of research throughout multiple years, continuing until 2024, marks it as a crucial platform for ongoing scientific dialogue and innovation, aimed at fostering better health outcomes for younger populations.

FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.

ACTA NEUROBIOLOGIAE EXPERIMENTALIS, an esteemed journal published by the Nencki Institute of Experimental Biology in Poland, has been a pivotal platform for the dissemination of research in the fields of medicine and neuroscience since its inception in 1970. With an ISSN of 0065-1400 and an E-ISSN of 1689-0035, this journal has consistently aimed to contribute to the understanding of neurobiological phenomena, cementing its status within the academic community. Despite its current categorization in the Q3 and Q4 quartiles for Medicine and Neuroscience respectively, ACTA NEUROBIOLOGIAE EXPERIMENTALIS continues to uphold rigorous scientific standards, providing an invaluable resource for researchers, professionals, and students alike. As an essential scholarly outlet, it encourages the exploration of groundbreaking findings and clinical applications in neurobiology, making it an attractive choice for those eager to advance their understanding of this intricate field.